The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Im, S.-H.
Right arrow Articles by Fuchs, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Im, S.-H.
Right arrow Articles by Fuchs, S.
The Journal of Immunology, 2000, 165: 3599-3605.
Copyright © 2000 by The American Association of Immunologists

Role of Tolerogen Conformation in Induction of Oral Tolerance in Experimental Autoimmune Myasthenia Gravis1

Sin-Hyeog Im*, Dora Barchan*, Miriam C. Souroujon*,{dagger} and Sara Fuchs2,*

* Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel; and {dagger} The Open University of Israel, Tel-Aviv, Israel

We recently demonstrated that oral or nasal administration of recombinant fragments of the acetylcholine receptor (AChR) prevents the induction of experimental autoimmune myasthenia gravis (EAMG) and suppresses ongoing EAMG in rats. We have now studied the role of spatial conformation of these recombinant fragments in determining their tolerogenicity. Two fragments corresponding to the extracellular domain of the human AChR {alpha}-subunit and differing in conformation were tested: H{alpha}1–205 expressed with no fusion partner and H{alpha}1–210 fused to thioredoxin (Trx), and designated Trx-H{alpha}1–210. The conformational similarity of the fragments to intact AChR was assessed by their reactivity with {alpha}-bungarotoxin and with anti-AChR mAbs, specific for conformation-dependent epitopes. Oral administration of the more native fragment, Trx-H{alpha}1–210, at the acute phase of disease led to exacerbation of EAMG, accompanied by an elevation of AChR-specific humoral and cellular reactivity, increased levels of Th1-type cytokines (IL-2, IL-12), decreased levels of Th2 (IL-10)- or Th3 (TGF-ß)-type cytokines, and higher expression of costimulatory factors (CD28, CTLA4, B7-1, B7-2, CD40L, and CD40). On the other hand, oral administration of the less native fragments H{alpha}1–205 or denatured Trx-H{alpha}1–210 suppressed ongoing EAMG and led to opposite changes in the immunological parameters. It thus seems that native conformation of AChR-derived fragments renders them immunogenic and immunopathogenic and therefore not suitable for treatment of myasthenia gravis. Conformation of tolerogens should therefore be given careful attention when considering oral tolerance for treatment of autoimmune diseases.




This article has been cited by other articles:


Home page
 Ann. N. Y. Acad. Sci.Home page
J. LINDSTROM, J. LUO, and A. KURYATOV
Myasthenia Gravis and the Tops and Bottoms of AChRs: Antigenic Structure of the MIR and Specific Immunosuppression of EAMG Using AChR Cytoplasmic Domains
Ann. N.Y. Acad. Sci., June 1, 2008; 1132(1): 29 - 41.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. Feferman, P. K. Maiti, S. Berrih-Aknin, J. Bismuth, J. Bidault, S. Fuchs, and M. C. Souroujon
Overexpression of IFN-Induced Protein 10 and Its Receptor CXCR3 in Myasthenia Gravis
J. Immunol., May 1, 2005; 174(9): 5324 - 5331.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Tramontano and S. P. Makker
Conformation and Glycosylation of a Megalin Fragment Correlate with Nephritogenicity in Heymann Nephritis
J. Immunol., February 15, 2004; 172(4): 2367 - 2373.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
M. MILANI, N. OSTLIE, W. WANG, and B. M. CONTI-FINE
T Cells and Cytokines in the Pathogenesis of Acquired Myasthenia Gravis
Ann. N.Y. Acad. Sci., September 1, 2003; 998(1): 284 - 307.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
M. C. SOUROUJON, P. K. MAITI, T. FEFERMAN, S.-H. IM, L. RAVEH, and S. FUCHS
Suppression of Myasthenia Gravis by Antigen-Specific Mucosal Tolerance and Modulation of Cytokines and Costimulatory Factors
Ann. N.Y. Acad. Sci., September 1, 2003; 998(1): 533 - 536.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. Psaridi-Linardaki, A. Mamalaki, M. Remoundos, and S. J. Tzartos
Expression of Soluble Ligand- and Antibody-binding Extracellular Domain of Human Muscle Acetylcholine Receptor alpha Subunit in Yeast Pichia pastoris. ROLE OF GLYCOSYLATION IN alpha -BUNGAROTOXIN BINDING
J. Biol. Chem., July 19, 2002; 277(30): 26980 - 26986.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
S.-H. IM, D. BARCHAN, P. K. MAITI, L. RAVEH, M. C. SOUROUJON, and S. FUCHS
Suppression of experimental myasthenia gravis, a B cell-mediated autoimmune disease, by blockade of IL-18
FASEB J, October 1, 2001; 15(12): 2140 - 2148.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S.-H. Im, D. Barchan, P. K. Maiti, S. Fuchs, and M. C. Souroujon
Blockade of CD40 Ligand Suppresses Chronic Experimental Myasthenia Gravis by Down-Regulation of Th1 Differentiation and Up-Regulation of CTLA-4
J. Immunol., June 1, 2001; 166(11): 6893 - 6898.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2000 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2000 by The American Association of Immunologists, Inc. All rights reserved.